Photo from Paolo Tarantino/Twitter
Aug 24, 2023, 18:16
Paolo Tarantino: Retrospective study by Viale et al. on HER2-low breast cancer.
Quoting Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, on Twitter:
”Just out on ESMO Open a global, retrospective study by Viale et al. on HER2-low (vs 0) breast cancer (n=789). No notable differences in features & outcomes were found between HER2-low vs HER2-0 cases. Upon rescoring, >30% of HER2-0 cases became HER2-low.”
For the article click here.
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19